Psoriasis: secukinumab shows sustained efficacy though 2 years

  • Thaçi D & al.
  • J Am Acad Dermatol
  • 6 Aug 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Secukinumab is associated with sustained skin clearance and QoL in patients with moderate to severe psoriasis, according to results from an open-label extension of the phase 3b CLEAR study.

Why this matters

  • Initial analysis of CLEAR had demonstrated superior efficacy for secukinumab vs ustekinumab (Stelara); this study demonstrated sustained long-term efficacy.

Key results

  • At 2 years, secukinumab was associated with:
    • 89.6% of patients achieving ≥75% improvement in Psoriasis Area and Severity Index (PASI 75).
    • 74.7% achieving PASI 90.
    • 47.4% achieving PASI 100.
    • 68.8% achieving Investigator’s Global Assessment 2011 modified version 0/1.
    • 66.0% achieving Dermatology Life Quality Index 0/1 (as-observed analysis).
  • Secukinumab was also associated with complete relief for pain, itching, and scaling in 70.9%, 47.4%, and 54.8% of patients, respectively, at 2 years (as-observed analysis).
  • Candida infection was reported in 7.2% of patients, whereas malignant or unspecified tumors were reported in 1.5% of patients.

Study design

  • 277 patients randomly assigned to receive secukinumab 300 mg from the original CLEAR cohort completed the 2-year extension.
  • Funding: Novartis Pharma AG.

Limitations

  • Open-label trial.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit